30 closest matches · ranked by relevance
Carcinoma of the Appendix · Primary Peritoneal Cavity Cancer
Primary: The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments…
Gynecologic Cancer · Gynecologic Neoplasms · Peritoneal Carcinomatosis
Primary: Proportion of Participants Who Are Successfully Down Staged to Resectable Based on Peritoneal Carcinomatosis Index (PCI) and Principal Investigator (PI) Discretion…
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Colorectal Cancer · Cancer of Gastrointestinal Tract
Primary: Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA) — 0; 0; 0; 2 Participants
Peritoneal Carcinomatosis
Primary: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by…
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Gastrointestinal Cancer
Primary: Number of Participants With Overall Response — 3; 12 participants
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Stage II Gallbladder Cancer · Stage IIIA Gallbladder Cancer · Stage IIIB Gallbladder Cancer
Primary: Response Rate According to RECIST Criteria — 3; 0 participants
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Carcinoma of the Appendix · Colorectal Cancer
Primary: Time to Progression — 0.775 years
Anal Cancer · Rectal Cancer
Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants
Appendicitis
Primary: Negative Appendectomy — 6; 6; 166; 180 participants
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Neoplasms, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 7.4; 8.5 months
Appendicitis · Perforated Appendicitis · Ruptured Appendicitis
Primary: Overall Cost of Care
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Gastrointestinal Cancer
Primary: Response Rate (RR) — 19 Participants
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Complicated Appendicitis · Acute Appendicitis
Primary: Feasibility of the Use of Antibiotic Solution Instillation Following Intraoperative Diagnosis of Complex Appendicitis as Assessed by Percentage of Eligible Participants…
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Neoplasm, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 12.6 months
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants